CV Science

1. Positions and Honors

Since 2011 Laboratoire de Neurobiologie et Développement, CNRS UPR 3294 (Director Dr. Ph.  Vernier), Institut de Neurobiologie Alfred Fessard, Gif sur Yvette, France

1996-2010 Laboratoire de Neurobiologie Cellulaire et Moléculaire, CNRS UPR 9040 (Director Dr. G. Baux), Gif sur Yvette, France

1992-1996 Laboratoire de Neurobiologie et Physiologie Comparées CNRS URA 1126, (Director Prof. Maurice Moulins), Arcachon , France

1985-1992 Laboratoire de Neurobiologie Cellulaire, CNRS URA 1136, (Director Prof. Herbert Koenig), Bordeaux, France

1981-1985 Laboratoire de Biologie et Pathologie Neuromusculaire, INSERM URA 153, Paris (Director Prof. M. Fardeau), France.

q  Expert for the Association Française contre les Myopathies, Italian Telethon Foundation, Israel Science Foundation, Muscular Dystrophy Campaign (England), Medical Research Council (Angleterre), and Muscular Dystrophy Association (USA)

q  Expert for the reviews Molecular Genetics and Metabolism, Synapse, J. of Biological Chemistry, Neuromuscular Disorders, American J. of Physiology, European J. of Pediatric Neurology

q  Member of the ethics committee (IEC): Comité de Protection des Personnes dans la Recherche Biomédicale (CPP) de Poissy –St Germain

1. Selected peer-reviewed publications (in chronological order).

Publications related to the subject

1. 1999-1 Chaubourt, E., P. Fossier, G. Baux, C. Leprince, M. Israel, and S. De La Porte. Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy. Neurobiol Dis., 1999, 6:499-507.
2. 2000-1 Chaubourt, E., Voisin, V., Fossier, P., Baux, G., Israël, M., De La Porte, S. The NO way to increase muscular utrophin expression ? C.R. Acad. Sci. Paris/Life Sciences, 2000, 323: 735-740.
3. 2000-2 Cifuentes-Diaz, C, Alliel, P., Charbonnier, F., De La Porte, S., Molgo, J., Goudou, D., Rieger, F., Périn, J-P. Regulated expression of the proteoglycan SPOCK in the neuromuscular system. Mechanisms of Development 2000, 94 (1-2): 277-282.
4. 2002-1 Chaubourt E, Voisin V, Fossier Ph, Baux G, Israël M, De La Porte S. Muscular nitric oxide synthase (muNOS) and utrophin. J. Physiol. (Paris), 96:43-52.
5. 2004-1 Touboul, D., Piednoël, H., Voisin, V., De La Porte, S., Brunelle, A., Halgand, F., Laprevote, O. Changes in phospholipid composition within the dystrophic muscle by matrix-assisted laser desorption/ionization mass spectrometry and mass spectrometry imaging. Eur. J. Mass Spectro., 10, 657-664.
6. 2004-1 Voisin, V., De La Porte S. Therapeutics strategies for Duchenne and Becker dystrophies. Int. Rev. Cytol., 240, 1-30.
7. 2005-1 Touboul, D., Brunelle, A., Halgand, F., De La Porte, S., Laprevote. Lipid imaging by gold time-of-flight secondary ion mass spectrometry: application to Duchenne muscular dystrophy. J. Lipid Res., 46, 1388-1395.
8. 2005-2 Voisin, V., Sébrié, C., Matecki, S., Yu, H., Gillet, B., Ramonatxo, M., Israël, M., De la Porte, S. L-arginine improves dystrophic phenotype in mdx mice. Neurobiol. Dis., 20,123-130.
9. 2005-3 Gillet, B., Sebrie, C., Bogaert, A., Bleneau, S., De La Porte, S. Beloeil J-C. Study of muscle regeneration using in vitro 2D¹H spectrometry. B.B.A. General Subjects, 1724, 333-344.
10. 2005-4 Voisin, V., De La Porte S. Traitement pharmacologique des myopathies de Duchenne et de Becker. J. Soc. Biol., 199, 17-28.
11. 2007-1 Tahallah N., Brunelle A,  De La Porte S, Laprévote  O. Lipid mapping in human dystrophic muscle by cluster-time-of-flight secondary ion mass spectrometry imaging. J. Lipid Res., 49, 438-454.
12. 2008 - Nnia K., Gayraud G., Hugon G., Ramonatxo M., De La Porte S., Matecki S, Mornet D. L-arginine decreases imflammation and modulates the nuclear factor-B/matrix metalloproteinase cascade in mdx muscle fibers. J. Am. Pathol., 172 : 1509-1519. FI : 5,9
13. 2008 - Tahallah N., Brunelle A,  De La Porte S, Laprévote  O. Lipid mapping in human dystrophic muscle by cluster-time-of-flight secondary ion mass spectrometry imaging. J. Lipid Res., 49, 438-454. FI : 4,34
14. 2010 - Guerron A.D., Rawat R., Sali A., Spurney C.F., Pistilli E., Cha H.J., Pandey G.S., Gernapudi R., Francia D.,  Farajian V., Escolar D., Bossi L, Becker M., Zerr P., De La Porte S, Gordish-Dressman H., Partridge T., Hoffman E.P. and Nagaraju K. (2010) « Functional and molecular effects of long term treatment of arginine butyrate and prednisone on skeletal muscle and heart in the mdx mouse model of Duchenne muscular dystrophy ». PLoS ONE, 5 (6): e11220
15. 2010 - Renaud S., Auffray J.-C., De La Porte S.  Epigenetic effects on the mouse mandible: common features and discrepancies in remodeling due to muscular dystrophy and response to food consistency. BMC Evolutionary Biology, 10 : 28

1. Research Support (related to the subject)

Ongoing Research Support

CNRS endowment 2011 : $8000

Pending Research Support

1. 2011 - IRF 144 NeuroSud Paris. Génération de modèles double KO de souris pour étudier le rôle du NO dans la mort cellulaire dépendante du Ca2+4 040 €. (Supplies, Purchase of animals, Missions).

Completed Research Support

1. 2009 - IRF 144 NeuroSud Paris. Effet d’un traitement pharmacologique inducteur d’utrophine sur des déficits moteurs et cognitifs de la souris mdx, modèle de la myopathie de Duchenne. 4 040 €. (Supplies, Purchase of animals).
2. 2008 -1 Association Française contre les Myopathies (AFM).Up-expression of utrophin gene via the nitric oxide (NO) pathway and the histone deacetylase(HDACs) inhibitor pathway. $10,094. (Supplies, missions)
3. 2007-1 Association Française contre les Myopathies (AFM).Up-expression of utrophin gene via the nitric oxide (NO) pathway and the histone deacetylase (HDACs) inhibitor pathway. $40,376. (salaries)
4. 2006-1 (January 2006 – December 2007) Muscular Dystrophy Association (MDA). ).Up-expression of utrophin gene via the nitric oxide (NO) pathway and the histone deacetylase (HDACs) inhibitor pathway. $64,000 (equipment, missions, supplies)
5. 2005-1 Association Française contre les Myopathies (AFM).Up-expression of utrophin gene via the nitric oxide (NO) pathway and the histone deacetylase (HDACs) inhibitor pathway. $90,202. (salaries, equipment, missions)
6. 2003-2, (July 2003 – July 2005). Muscular Dystrophy Association (MDA). Finding the best NO-related compound for treating Duchenne and Becker dystrophies. $70,350. (equipment, supplies, missions)
7. 2003-1 Association Française contre les Myopathies (AFM), Arginine derivatives and NO donors for the treatment of Duchenne Muscular Dystrophy. $59,500. (salaries, supplies)
8. 2001-2, (July 2001 – July 2003). Muscular Dystrophy Association (MDA), The NO pathway to increase utrophin expression: a potential treatment for Duchenne Dystrophy?, $70,000 (equipment, supplies, missions)
9. 2001-1, Association Française contre les Myopathies (AFM),  L’effet de la L-arginine sur l’expression de l’utrophine, $210,000 (salaries, equipment, supplies, missions)
10. 2000 -2- Conseil Général de l’Essonne. $25,000. « Traitement potentiel des myopathies de Duchenne et de Becker par activation de la voie du monoxyde d’azote »
11. 2000 -1- Association Française contre les Myopathies (AFM). $31,000 « Nitric oxide and L-arginine cause an accumulation of utrophin at the sarcolemma : a potential treatment for Duchenne and Becker muscular dystrophies ».
12. 1999 - Association Française contre les Myopathies (AFM). $31,000 « Surexpression de l’utrophine par les inducteurs de NO ».
13. 1998, Association Française contre les Myopathies (AFM), $10,400 “Surexpression de l’utrophine par les inducteurs de NO”